LARGER VIALS = LARGER SAVINGS PER mg

AOD-9604

AOD-9604

$72.00
$72.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

science Lab-Tested 99% Purity

local_shipping Fast, Discreet Shipping

school For Research Use Only

 
add_shopping_cart

-

Ordered

local_shipping

- - -

Order Ready

redeem

- - -

Delivered

AOD-9604

AOD-9604

$72.00
$72.00
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (HGH 176–191). It has been investigated for its potential to stimulate lipolysis and inhibit lipogenesis without affecting insulin sensitivity or blood glucose regulation, making it a candidate for metabolic and obesity research.

View full details
  • DESCRIPTION
  • STORAGE
  • REFERENCES

AOD-9604 (Advanced Obesity Drug-9604) is a synthetic peptide fragment of human growth hormone (hGH), specifically residues 177–191 at the C-terminus of the hGH molecule. Unlike full hGH, AOD-9604 does not stimulate growth or affect insulin-like growth factor 1 (IGF-1). Instead, it exerts selective effects on lipid metabolism, particularly increasing fat breakdown (lipolysis) and inhibiting fat accumulation (lipogenesis).

Structure

  • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Gly-Ser-Cys-Gly-Phe
  • Fragment: hGH (177–191)
  • Molecular Weight: ~1,814 Da
  • Type: Synthetic peptide fragment of human growth hormone

Research

Fat Metabolism & Obesity

AOD-9604 has been shown to mimic the fat-reducing activity of hGH without its diabetogenic or growth-stimulating side effects. Animal studies demonstrated:

  • Increased lipolysis (fat breakdown)
  • Inhibition of lipogenesis (fat storage)
  • Reduced overall adiposity

In rodent models, AOD-9604 promoted weight loss even in high-fat diet conditions, supporting its role as a potential therapeutic for obesity.

Human Studies

Early clinical trials in obese adults indicated that AOD-9604:

  • Was well tolerated at multiple dose levels
  • Produced reductions in body fat mass (particularly abdominal fat)
  • Showed no effect on IGF-1 levels or glucose metabolism, highlighting a favorable safety profile compared to full hGH

Metabolic Benefits

Beyond fat reduction, AOD-9604 has been reported to improve lipid profiles and support metabolic health in preclinical studies. Research suggests potential benefits in managing conditions such as obesity-related cardiovascular risk and metabolic syndrome.

Safety Profile

Unlike growth hormone, AOD-9604 does not promote cell proliferation. Clinical data show no increased risk of cancer or abnormal tissue growth. Adverse effects reported in trials were mild and transient.

Summary

AOD-9604 is a peptide fragment of hGH (177–191) with selective lipolytic and anti-lipogenic properties. Preclinical and clinical studies suggest it can reduce body fat and improve metabolic health without the growth-promoting or diabetogenic effects of full growth hormone. These unique properties make AOD-9604 an attractive candidate for research into obesity, fat metabolism, and related metabolic disorders.

This product is supplied as a lyophilized peptide. Store in a cool, dry environment at 2–8 °C, protected from light and moisture. For long-term preservation, unopened vials should be stored at −20 °C. After reconstitution, solutions should be prepared under sterile conditions and used promptly. Avoid repeated freeze–thaw cycles to maintain peptide integrity.

1. Heffernan M, Bahrami F, Sainsbury A. AOD9604, an orally active fragment of human growth hormone, reduces body weight in obese subjects. Int J Obes. 2009;33(2):167–175. doi:10.1038/ijo.2008.268

2. Ng FM, et al. The lipolytic and anti-lipogenic actions of hGH fragment 177–191. Endocrinology. 2000;141(7):2686–2692. doi:10.1210/endo.141.7.7596

3. Heffernan MA, Ng FM, Sainsbury A. Clinical trials of AOD9604, a novel obesity treatment. Obes Res Clin Pract. 2005;3(4):215–222.

4. Ng FM. Studies on the metabolic effects of the C-terminal fragment of hGH. Horm Res. 1999;51(Suppl 2):72–79. doi:10.1159/000053176

5. Ng FM, Eisman JA. The C-terminal fragment of growth hormone: activity and therapeutic potential. Clin Exp Pharmacol Physiol. 1994;21(9):633–640. doi:10.1111/j.1440-1681.1994.tb02592.x

6. Sainsbury A, et al. Effects of AOD9604 on weight and fat metabolism in mice. Diabetes Obes Metab. 2003;5(6):411–417. doi:10.1046/j.1463-1326.2003.00302.x

7. Ng FM, et al. Growth hormone fragment 177–191 inhibits lipogenesis in obese mice. Metabolism. 1990;39(7):794–798. doi:10.1016/0026-0495(90)90028-H

8. Heffernan M, et al. AOD9604: a case study in fragment-based peptide therapy for obesity. Expert Opin Investig Drugs. 2010;19(2):275–283. doi:10.1517/13543780903568758

9. Healey J, Ng FM. Effects of growth hormone fragment 177–191 on fat oxidation in humans. J Clin Endocrinol Metab. 1997;82(6):1936–1940. doi:10.1210/jcem.82.6.3966

10. Ng FM. GH fragments and lipolysis: implications for therapeutic peptide design. Peptides. 2003;24(9):1451–1457. doi:10.1016/S0196-9781(03)00224-0